Kornimate/medical-research-clean huggingface dataset:
the impact of two different physical therapy programs in the rehabilitation of patients undergoing anterior approach hip replacement surgery

Conditions: Hip Arthritis; Total Hip Arthroplasty

Summary: this study will look to determine two different types of physical therapy regimens in patients who undergo anterior total hip replacement. we will compare the results of two groups. the first group, the "formal physical therapy" group, will undergo standard physical therapy following their surgery. they will see a physical therapist in a physical therapy office after their surgery. here, the therapist will work with the patient to strengthen muscles and improve their walking. the second group, the "self-directed physical therapy" group, will undergo physical therapy in the comfort of their own home using common household items (chairs, steps, etc). these patients will be given a list of exercises and stretches to perform on their own. it is our goal to prove that formal physical therapy is not needed after anterior hip replacements.


Eligibility criteria:
inclusion criteria: * patients aged between 18 and 80 years of age * patients undergoing primary anterior total hip arthroplasty for the diagnosis of osteoarthritis * patients with no previous invasive hip surgery (such as a previous hip replacement) exclusion criteria: * non-english speaking persons will be excluded in our study. * patients with a recent history (\<1 year) of heart attack, stroke, and lung clots. * previous invasive surgery on the hip undergoing replacement * patients with dementia, parkinson's, or other neurological disorders * non-ambulatory patients * patients with impaired ability to consent, whether because of mental illness or otherwise * patients being discharged to a rehabilitation center * patients that experience intra-operative complications

Keywords: total hip arthroplasty anterior approach physical therapy
the impact of injustice appraisals on psychosocial outcomes following spinal cord injury: a longitudinal study

Conditions: Spinal Cord Injuries

Summary: the primary objectives of this study are to: (1) determine the longitudinal course and impact of injury-related injustice appraisals among civilians and veterans who have recently acquired a spinal cord injury (sci), and (2) use qualitative inquiry to gain a rich, contextual understanding of appraisals of injustice during the first year after acquired sci. the long-term goal of this research is to inform the development of new treatment approaches targeting appraisals of injustice.

at present, there are no interventions that specifically target appraisals of injustice, and there is limited research upon which to recommend clinical interventions to mitigate the impact of injustice appraisals on rehabilitation outcomes. treatment techniques currently being used within multidisciplinary rehabilitation programs do not yield clinically meaningful reductions in perceptions of injustice. findings from the proposed study will inform the development of interventions targeting injustice appraisals and associated sequelae. given the lack of research in this domain, as well as the absence of interventions to address injustice appraisals following injury, the proposed study will make a significant contribution to our current understanding of mechanisms that impact psychosocial and functional outcomes following spinal cord injury to inform future interventions.

Eligibility criteria:
inclusion criteria: * have acquired a spinal cord injury (sci) in the past 6 months * admitted for first inpatient rehabilitation hospitalization exclusion criteria: * sci without neurological impairment
ketamine as an adjunctive therapy for major depression

Conditions: Major Depressive Episode; Unipolar Depression; Bipolar Depression

Summary: randomised, controlled, parallel-group, pilot clinical trial of ketamine vs. midazolam as an adjunctive therapy for depression. the main purpose of the pilot study is to assess trial processes to help inform a future definitive trial.

pragmatic, randomised, controlled, parallel-group, pilot trial. trial participants will be patients admitted to st patrick's university hospital for treatment of a depressive episode. the investigators aim to recruit up to 20 participants who will be eligible for this study and randomly allocate 10 patients to each group. the participants will undergo usual inpatient care as prescribed by their treating team for the index acute depressive episode. both participants and assessors will be blind to treatment allocation. consented participants will be randomly allocated in a 1:1 ratio to a four week course of either once-weekly ketamine or midazolam infusions. block randomisation will be independently performed. physical, psychotomimetic and cognitive outcomes will be monitored before, during and after infusions. blood samples will be taken at four time-points in the first infusion session and before the final infusion for neuroplasticity biomarker studies. both groups will continue treatment as usual. participates will also be followed up over a three month period.

Eligibility criteria:
inclusion criteria: * ≥18 years old * hamilton rating scale for depression-24 item version (hrsd-24) score of ≥21 * voluntary admission for treatment of an acute depressive episode * meet diagnostic and statistical manual of mental disorders , fifth edition (dsm-v) criteria for a major depressive disorder (mdd) and bipolar affective disorder (current episode depression) exclusion criteria: * current involuntary admission * medical condition rendering unfit for ketamine/midazolam * active suicidal intention * dementia * history of axis 1 diagnosis other than major depression * electroconvulsive therapy (ect) administered within the last two months * alcohol/substance dependence in previous six-months * pregnancy or inability to confirm use of adequate contraception during the trial * breastfeeding women

Keywords: ketamine glutamate
effect of science research wellness ndo1 on glycaemia in adults with pre-diabetes

Conditions: Prediabetes

Summary: the objective of this study is to test the effect of 12 weeks of supplementation srw ndo1 on metabolic health and general health in adults with prediabetes. the primary question it aims to answer are: * how does srw ndo1 affect the haemoglobin a1c (hba1c) test outcome for adult individuals? * how does srw ndo1 affect the body measures and blood pressures of adult individuals? investigators will compare the supplement to a placebo (a look-alike substance that contains no supplement) to see if srw ndo1 works to support normal blood sugar metabolism. participants will: * take supplement srw ndo1, two capsules a day for 12 weeks. * be asked to refrain from changing their diet and lifestyle drastically during the study and to refrain from starting new health supplements during the study. * visit the clinic at the start and the end of intervention for a blood test (8 hour fasting required prior to test) * keep a diary of their symptoms or adverse events during intervention.


Eligibility criteria:
inclusion criteria: 1. age 18 years and over. 2. prediabetes, defined as fasting plasma glucose of 6.1-6.9 mmol/l and/or hba1c of 5.7-6.4% and/or 2 h plasma glucose of 7.8-11.0 mmol/l after ingestion of 75 g of oral glucose load. blood tests conducted within 3 months before randomisation will be accepted. 3. able to read and write english. 4. has access to internet. 5. provided informed consent to participate in the study. exclusion criteria: 1. has a medical condition known to affect the glycaemia. 2. regular intake of a health supplement with effects on glycaemia. 3. currently participating in another trial/study of a supplement or drug. 4. has any known food or allergy or intolerances to the ingredients of the intervention. 5. pregnant, trying to conceive or breastfeeding. 6. has any current substance abuse (including tobacco, alcohol and recreational drugs) or currently in substance withdrawal. 7. moderate to severe medical conditions (defined as a significant impact on social areas of functioning). 8. any medical conditions that was not stable over the last 3 months. 9. taking any prescription medication known to affect glycaemia or had a change in their medication within the last 3 months. 10. currently taking celiprolol, metformin, or any angiotensin-converting enzyme inhibitor medications. 11. major medical or surgical event requiring hospitalization within the last 3 months. 12. any other medical reason that may make participation in this study pose a risk to the participant, including potential herb-drug interactions, at the discretion of the study medical supervisor.

Keywords: diabetes prediabetes
a clinical trial to demonstrate the efficacy of cangrelor

Conditions: Myocardial Infarction (MI); Acute Coronary Syndromes (ACS)

Summary: the primary objective of this study is to demonstrate that the efficacy of cangrelor is superior, or at least non-inferior, to that of clopidogrel in subjects requiring pci.


Eligibility criteria:
inclusion criteria to be included in this study, subjects must meet the following criteria: * angiography demonstrating atherosclerosis amenable to treatment by percutaneous coronary intervention (pci) with or without stent implantation and diagnosis of acute coronary syndrome (acs) by elevated cardiac markers or ischemic chest discomfort w/electrocardiogram changes + age \> 65 or diabetes or st-elevation mi. exclusion criteria subjects will be excluded from the study if they present with any of the following: 1. not a candidate for pci 2. increased bleeding risk: ischemic stroke within the last year or any previous hemorrhagic stroke, tumor, cerebral arteriovenous malformation, or intracranial aneurysm; recent (\<1 month) trauma or major surgery (including by-pass surgery); currently receiving warfarin, active bleeding 3. impaired hemostasis: known international normalized ratio (inr) \>1.5 at screening; past or present bleeding disorder (including congenital bleeding disorders such as von willebrand's disease or hemophilia, acquired bleeding disorders, and unexplained clinically significant bleeding disorders), thrombocytopenia (platelet count \<100,000/µl), or history of thrombocytopenia or neutropenia associated with clopidogrel 4. severe hypertension not adequately controlled by antihypertensive therapy at the time of randomization 5. receipt of fibrinolytic therapy in the 12 hours preceding randomization 6. receipt of clopidogrel dose exceeding maintenance dose (ie, \>75 mg) at any time in the 5 days preceding randomization 7. inability to swallow study capsules 8. glycoprotein iib/iiia (gpi) inhibitor usage within the previous 12 hours \[applicable to unstable angina (ua) and non-st-elevation myocardial infarction (nstemi) patients\] subjects excluded for any of the above reasons may be re-screened for participation at any time if the exclusion characteristic has changed.

Keywords: acute coronary syndrome (acs) percutaneous coronary intervention (pci) non-st-segment elevation myocardial infarction (nstemi) st-segment elevation myocardial infarction (stemi)
vitamin d supplementation in episodic and chronic tension-type headache

Conditions: Chronic Tension-Type Headache

Summary: the goal of this clinical trial is to learn about the effect of vitamin d in patients with prophylactic therapy for episodic and chronic tension-type headache in amitriptyline or topiramate treatment. the main question it aims to answer are: • what is the effect of vitamin d in patients with prophylactic therapy for episodic and chronic tension-type headache? patients will have the next selection criteria: * patients diagnosed by a neurologist in the headache clinic * criteria for episodic and chronic tension-type headache * poor clinical response to prophylactic treatment (amitriptyline, topiramate) * use of at least 1 prophylactic medication or a history of having used them. * onset of disease between the ages of 18 and 60 * signature of informed consent the population will be randomly divided into the following 3 treatment groups: * participants amitriptyline or topiramate treatment. * patients with placebo (calcium) + topiramate/amitriptyline, * participants with vitamin d3/calcium+topiramate/amitriptyline. researchers will compare the groups to see if vitamin d can decrease the intensity of your headache and therefore have a new therapeutic option.

it will be a 4 month study. each month a package containing treatment will be delivered, which may be conventional medication or tablets with conventional medication added with vitamins.

Eligibility criteria:
inclusion criteria: * patients diagnosed by a neurologist in the headache clinic * criteria for episodic and chronic tension-type headache * poor clinical response to prophylactic treatment (amitriptyline, topiramate) * use of at least 1 prophylactic medication or a history of having used them. * onset of disease between the ages of 18 and 60 * signature of informed consent exclusion criteria: * patients with secondary headache (cranioencephalic trauma, cerebral infarction) * patients with primary headache other than tension headache * suffer heart, liver, and kidney diseases. * medications: thiazides * pregnant women * they do not want to participate
ipack block for total knee arthroplasty

Conditions: Knee Osteoarthritis; Knee Pain Chronic; Knee Disease

Summary: this randomized, double-blinded, placebo-controlled trial seeks to evaluate the efficacy of the rehabilitation process of the interspace between the popliteal artery and capsule of the posterior knee (ipack) block in total knee arthroplasty.

the interspace between the popliteal artery and capsule of the posterior knee (ipack) block, has been recently described and shows promise in providing analgesia to the knee joint. the effect of this block on postoperative rehabilitation is uncertain. this study aims to compare a preoperative ipack block to a placebo block prior to total knee arthroplasty under spinal anesthesia. the primary outcome measure is verticalization, walking distance, ability to go out of bed, active lifting of the limb, range of motion in the hip joint, bending range of motion, and abduction range of motion. the secondary measure is postoperative pain assessment during rehabilitation.

Eligibility criteria:
inclusion criteria: * patients \> 18 years old undergoing unilateral total knee arthroplasty exclusion criteria: * refusal to participate * \< 18 yo * chronic opioid use * localized infection

Keywords: ipack block regional anesthesia multimodal analgesia total knee arthroplasty
cobra: cancer, older adults, balance and resistance activities

Conditions: Primary Cancer; Metastatic Cancer; Cancer

Summary: the purpose of this study is to find out whether an 8-week digital health promotion program called cobra is a safe and practical (feasible) option for older adults with cancer/oac.


Eligibility criteria:
inclusion criteria: older adult patients with cancer - are within 1 year of completion of primary therapy for cancer or have a diagnosis of metastatic cancer; 1. for the purpose of this study, primary therapy is defined as treatment of curative intent, first-line or later, from which the individual is advancing to active surveillance or follow-up with or without maintenance therapy. 2. individuals with metastatic cancer may be included provided they have stable disease or better per most recent restaging exam at time of enrollment. i. patients with stable metastatic bony disease at most recent restaging exam and a score of 0-2 on the functional pain scale (fps69; appendix 18) are eligible. the pi will consult with the rehab med co-pi for fps scores of 3 or greater, by patient request or pi discretion. ii. patients with symptomatic visceral metastases will be evaluated on a case-by-case basis at time of enrollment. * are aged 65 years and older, with no upper age limit; * ecog ps 0-3 or karnofsky ps greater than or equal to 40; * can read and speak english; * self-report access to internet connection sufficient to support videoconferencing. clinicians * licensed clinician (md, rn, app) with an interest in the care of older adults with cancer. exclusion criteria: older adult patients with cancer * have any cognitive impairment, neurologic, musculoskeletal, or other comorbid condition (as assessed by their provider) that would prevent the individual from engaging with the digital health coaching program or complete study assessments or engage in progressive intensity levels of physical activity * have a neurologic, musculoskeletal, or other comorbid condition that would impede their ability to safely engage in progressive intensity levels of physical activity (as assessed by their provider). patients with metastatic disease and suspected interim progression since last restaging exam will be referred back to their primary oncology care team for evaluation prior to enrollment. * have activity restrictions post-surgery at the time of enrollment clinicians no expected exclusions

Keywords: primary cancer metastatic cancer cancer 25-090 memorial sloan kettering cancer center
effects of beef consumption on skeletal muscle protein homeostasis and inflammatory factors in pre- and postmenopausal females

Conditions: Menopause Related Conditions

Summary: this will be a randomized study to determine if animal-based protein-rich food sources can stimulate greater muscle protein turnover and whole-body protein balance and reduce skeletal muscle inflammatory markers in postmenopausal women compared to vegetarian base protein-rich foods.

a randomized cross-sectional controlled trial will be conducted to quantify whole-body and muscle protein turnover and skeletal muscle inflammation following 5-days of consumption of either beef or isonitrogenous plant-based sources of protein in normal/overweight and obese post-menopausal females. a premenopausal normal/overweight group consuming beef containing study meals will also be recruited to serve as a healthy control comparison.

Eligibility criteria:
inclusion criteria: 1. postmenopausal women ages 50-65 (absence of menstruation for at least 12 months). 2. premenopausal women ages 35-45 (presence of normal monthly menstruation for the past 12 months). 3. bmi of 20.0 - 34.9 kg/m2. 4. covid-19 negative and/or asymptomatic exclusion criteria: 1. any substantial musculoskeletal injuries/diseases that have limited daily activities in the past month. 2. unable to stop the use of anti-inflammatory drugs for the week prior to and during study. 3. diagnosed metabolic or hormonal disease (i.e., renal, cardiovascular, thyroid, polycystic ovary syndrome, or type i/ii diabetes mellitus). 4. currently pregnant. 5. gave birth or was lactating within previous 12 months. 6. undergone gastric bypass/bariatric surgery. 7. clinically significant weight gain or loss (\>5% change) in the last 12 months. 8. consuming metabolism-altering drugs or medications (i.e., corticosteroids, stimulants, insulin, thyroid medication). 9. unable or unwilling to suspend anti-clotting medications including aspirin use for 5 days prior to visit 4. 10. participating in \>200 minutes/week of vigorous exercise and/or \>4 days/week of resistance training. 11. unwilling to fast overnight. 12. surgical menopause. 13. having undergone hormone replacement therapy in the last 12 months.
poc study of obe022 in threatened preterm labour

Conditions: Preterm Labor

Summary: this is a proof-of-concept study in 2 parts. in part a, patients will receive obe022 open-label in order to assess the safety and pharmacokinetics in pregnant women with spontaneous preterm labour with a gestational age between 28 0/7 and 33 6/7 weeks. part b has a double-blind, randomised, placebo controlled, parallel group and multicentre design and will assess the efficacy, safety and pharmacokinetics in pregnant women with threatened spontaneous preterm labour with a gestational age between 24 0/7 and 33 6/7 weeks. all patients in part a and part b must receive atosiban infusion for 48 hours as standard of care treatment. patients from part a will receive obe022 open label. patients from part b will be randomised to receive obe022 or matching placebo. imp treatment duration will be up to 7 days. imp treatment will be stopped in case of delivery prior to day 7.


Eligibility criteria:
key inclusion criteria: part a * pregnant females aged ≥ 18 years * patients with a singleton or twin pregnancy * gestational age between 28 0/7 and 33 6/7 * administered or prescribed atosiban for the treatment of preterm labour part b * pregnant females aged ≥ 18 years * patients with a singleton or twin pregnancy * gestational age between 24 0/7 and 33 6/7 * administered or prescribed atosiban for the treatment of preterm labour * ≥4 uterine contractions per 30 minutes * cervical dilatation of 1 to 4 cm inclusive * at least one of the following signs of preterm labour: 1. positive igfbp-1 or fœtal fibronectin test 2. cervical length ≤ 25mm 3. progressive cervical change key exclusion criteria: * fœtal death in utero in current or previous pregnancy after gestational week 24 or expected high risk of fœtal death in the coming days * oligohydramnios * known pathological doppler ultrasound of the umbilical artery * any contraindications for the mother or the fœtus to stop labour or prolong pregnancy or any maternal or fœtal conditions likely to indicate iatrogenic delivery in the next 7 days, including but not limited to: 1. premature rupture of membranes 2. evidence or suspicion of abruptio placenta 3. signs and/or symptoms of chorio-amnionitis 4. pre-eclampsia, eclampsia or hellp-syndrome * use of cervical cerclage in the current pregnancy or a pessary in situ * current use of anti-hypertensive medication * treatment with other tocolytics within specified time before the baseline assessment of uterine contractions

Keywords: preterm labor preterm birth premature birth tocolysis prostaglandin f2α antagonist pgf2α tocolytic
intense pulsed light in meibomian gland dysfunctions

Conditions: Dry Eye Syndromes; Meibomian Gland Dysfunction

Summary: dry eye disease (ded) is an extremely common disease whose meibomian gland dysfunction is the main etiology. polychromatic intense pulsed light (ipl) is a promising new therapeutic alternative but few clinical data have been published. a new ipl device has recently been marketed: lacrystim (quantel, france). the investigators have been using it in our clinical practice since june 2019. the investigators present a retrospective study on our first clinical results.


Eligibility criteria:
inclusion criteria: * patients with dry eye disease with meibomian gland dysfunction, preferentially mild to moderate, and having benefited from intense pulsed light treatment. * patient affiliated with a social security organization exclusion criteria: * patient with incomplete follow-up

Keywords: intense pulsed light